JNJ received EU approval for PONVORY in relapsing multiple sclerosis and also a U.S. approval of RYBREVANT for the treatment of patients with locally...
Remdesivir was launched in India and have ramped up supplies to meet with the higher demand due to surge of the COVID cases in...
TLRY has launched a new product collaboration ith Canada’s leading craft cannabis brand, Broken Coast, a brand under the Tilray portfolio based in British...
Teva is a global pharmaceutical company, committed to helping patients around the world to access affordable medicines and benefit from innovations to improve their...
The company announced new data from the randomized, double blind, placebo controlled BLAZE 1 Phase 3 study, demonstrating bamlanivimab and etesevimab together reduced COVID...
AbbVie announced that the FDA extended the review period for the supplemental New Drug Applications ( sNDA ) for Rinvoq in the treatment of...
Pfizer has emerged as a leader in mRNA development, and is exploring a wide range of opportunities for the technology. They aim to develop...
PONVORY ( ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses...
Bausch Pharma, announced a statistically significant top line results from the second Phase 3 trial of IDP 126 gel, which is anti bacterial and...
Exploration of LUMAKRAS in multiple Phase 1b combination cohorts continues to progress with more than 10 combinations now underway. The company is initiating triplet...
Boutique equity research firm providing Business, Investment and M&A research services focused on fast growing Technology, Healthcare, Life science and Industrial sectors.